Denali Therapeutics Inc (DNLI)
15.55
-0.54
(-3.36%)
USD |
NASDAQ |
Apr 24, 16:00
15.55
0.00 (0.00%)
After-Hours: 19:33
Denali Therapeutics Cash from Operations (TTM): -357.99M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -357.99M |
September 30, 2023 | -332.00M |
June 30, 2023 | -301.68M |
March 31, 2023 | -231.41M |
December 31, 2022 | -244.72M |
September 30, 2022 | -237.55M |
June 30, 2022 | -221.94M |
March 31, 2022 | -233.26M |
December 31, 2021 | -211.39M |
September 30, 2021 | 368.02M |
June 30, 2021 | 409.54M |
March 31, 2021 | 420.40M |
December 31, 2020 | 416.15M |
Date | Value |
---|---|
September 30, 2020 | -145.41M |
June 30, 2020 | -175.93M |
March 31, 2020 | -175.74M |
December 31, 2019 | -151.58M |
September 30, 2019 | -10.75M |
June 30, 2019 | -15.14M |
March 31, 2019 | -13.78M |
December 31, 2018 | 50.12M |
September 30, 2018 | -61.40M |
June 30, 2018 | -48.50M |
March 31, 2018 | -24.25M |
December 31, 2017 | -76.64M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-357.99M
Minimum
Dec 2023
420.40M
Maximum
Mar 2021
-75.39M
Average
-175.93M
Median
Jun 2020
Cash from Operations (TTM) Benchmarks
Halozyme Therapeutics Inc | 388.57M |
AIM ImmunoTech Inc | -21.27M |
Perspective Therapeutics Inc | -36.91M |
Protalix BioTherapeutics Inc | -1.318M |
Armata Pharmaceuticals Inc | -47.42M |